PBYI Puma Biotechnology, Inc.

NASDAQ
$9.77

Puma Biotechnology, Inc. (PBYI) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.9% since its last earnings release on August 6, 2026.

Puma Biotechnology Beat Consensus Estimates, Raises Guidance, but Remains In-line with Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs $0.06
Rev est $57.12M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.20

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Puma Biotechnology, Inc.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.